CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T 细胞疗法代表了某些类型血液肿瘤患者预后和治疗的一场治疗革命。然而,它们也在医疗、监管和财务领域带来了新的挑战。RET-A项目的目的是对西班牙国家卫生系统内CAR-T 疗法的管理进行战略反思,以达成有助于在当前和未来更好地应对这些细胞疗法所带来的新环境的建议。该智库汇集了40位关键参与者和意见领袖。专家们确定了在西班牙实施先进疗法的三大挑战:以多学科方法实现治疗个体化;通过最大限度减少官僚程序来加快可及时间;以及增加NHS内有资格管理CAR-T 疗法的中心数量。专家们就指定这些合格中心的理想标准达成了一致。他们还就一个全面的CAR-T 诊疗路径达成了一致,包括该流程每个部分理想情况下所涉及的时间节点和角色。
CAR-T cell therapy represents a therapeutic revolution in the prognosis and treatment of patients with certain types of hematological cancer.
However, they also pose new challenges in the healthcare, regulatory and financial fields. The aim of the RET-A project was to undertake a strategic reflection on the management of CAR-T therapies within the Spanish National Health System, to agree on recommendations that will help to better deal with the new context introduced by these cell therapies in the present and in the future. This think tank involved 40 key agents and opinion leaders.
The experts identified three great challenges for implementing advanced therapies in Spain: therapeutic individualisation, with a multidisciplinary approach; acceleration of access times, by minimizing bureaucracy; and increase in the number of centers qualified to manage the CAR-T therapies in the NHS. The experts agreed on the ideal criteria for designating those qualified centers. They also agreed on a comprehensive CAR-T care pathway with the timings and roles which would ideally be involved in each part of the process.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。